See more : IGO Limited (IIDDY) Income Statement Analysis – Financial Results
Complete financial analysis of Akso Health Group (HX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akso Health Group, a leading company in the Medical – Distribution industry within the Healthcare sector.
- Powertap Hydrogen Capital Corp. (MOTNF) Income Statement Analysis – Financial Results
- Azkoyen, S.A. (AZK.MC) Income Statement Analysis – Financial Results
- European Biotech Acquisition Corp. (EBAC) Income Statement Analysis – Financial Results
- Kuwait Finance House K.S.C.P. (KFH.KW) Income Statement Analysis – Financial Results
- Chicago Atlantic BDC, Inc. (LIEN) Income Statement Analysis – Financial Results
Akso Health Group (HX)
About Akso Health Group
Hexindai Inc. is a holding company, which engages in the operation of online marketplace connecting borrowers and investors. The company is headquartered in Beijing, Beijing and currently employs 552 full-time employees. The firm is focused on offering borrowers a range of products designed-based on customer segmentation data and tailored to the specific needs of the emerging middle class in China. The firm also offers five tailored loan products such as Provident Fund Loans, Property-Owner Loans, Car-Owner Loans, Insurance-Holder Loans, and Premier Customer Loans. The firm offers products and services to Borrowers, and Investors.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41M | 13.18M | 6.31M | 1.75M | 11.44M | 61.33M | 107.26M | 22.92M | 11.89M | 4.65M |
| Cost of Revenue | 2.29M | 11.91M | 5.39M | 544.57K | 4.99M | 7.40M | 8.50M | 5.15M | 2.36M | 1.61M |
| Gross Profit | 122.13K | 1.27M | 916.23K | 1.21M | 6.44M | 53.93M | 98.76M | 17.77M | 9.54M | 3.04M |
| Gross Profit Ratio | 5.06% | 9.63% | 14.52% | 68.97% | 56.33% | 87.94% | 92.08% | 77.53% | 80.17% | 65.44% |
| Research & Development | 0.00 | -0.99 | 421.19K | 544.57K | 1.03M | 0.00 | 2.82M | 5.15M | 2.36M | 1.61M |
| General & Administrative | 8.59M | 15.53M | 15.39M | 27.27M | 26.80M | 16.51M | 7.64M | 2.65M | 1.55M | 733.92K |
| Selling & Marketing | 168.42K | 6.66K | 240.93K | 1.09M | 16.47M | 32.32M | 15.24M | 5.21M | 3.84M | 2.61M |
| SG&A | 8.76M | 15.54M | 15.63M | 28.36M | 43.27M | 48.84M | 22.89M | 7.86M | 5.39M | 3.34M |
| Other Expenses | 0.00 | 1.20M | -780.55K | -164.92K | 1.60M | 2.31M | 660.88K | 179.53K | 26.27K | -7.70K |
| Operating Expenses | 8.76M | 15.54M | 16.05M | 28.36M | 43.27M | 48.84M | 22.89M | 7.86M | 5.39M | 3.34M |
| Cost & Expenses | 11.05M | 27.45M | 21.44M | 28.90M | 48.26M | 56.23M | 31.38M | 13.01M | 7.75M | 4.94M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.12K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 804.14K | 2.15M | 2.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 138.24K | 18.39K | 18.39K | 15.16K | 120.52K | 406.80K | 174.38K | 92.22K | 61.39K | 19.70K |
| EBITDA | -8.50M | -14.25M | -3.26M | -2.07M | -18.80M | -6.79M | 76.05M | 10.01M | 4.20M | -278.92K |
| EBITDA Ratio | -352.06% | -99.13% | -251.87% | -1,555.58% | -302.99% | 8.31% | 70.74% | 43.65% | 35.33% | -6.00% |
| Operating Income | -8.64M | -14.27M | -15.13M | -27.15M | -36.83M | 5.10M | 75.88M | 9.91M | 4.14M | -298.63K |
| Operating Income Ratio | -357.78% | -108.23% | -239.79% | -1,547.05% | -322.05% | 8.31% | 70.74% | 43.25% | 34.81% | -6.43% |
| Total Other Income/Expenses | -453.75K | 1.20M | -747.82K | -3.92M | 1.23M | 381.15K | 660.88K | 179.53K | 26.27K | -7.70K |
| Income Before Tax | -9.09M | -13.07M | -16.72M | -31.07M | -66.93M | 7.41M | 76.54M | 10.09M | 4.17M | -306.33K |
| Income Before Tax Ratio | -376.57% | -99.13% | -264.90% | -1,770.39% | -585.30% | 12.07% | 71.36% | 44.04% | 35.03% | -6.59% |
| Income Tax Expense | 24.99K | 17.55K | 131.43K | 482.98K | 4.27M | 1.87M | 11.03M | 1.52M | 628.25K | 43.84K |
| Net Income | -9.46M | -13.08M | -16.85M | -31.55M | -71.20M | 5.53M | 65.48M | 8.57M | 3.54M | -350.17K |
| Net Income Ratio | -391.78% | -99.26% | -266.99% | -1,797.92% | -622.63% | 9.02% | 61.05% | 37.39% | 29.75% | -7.54% |
| EPS | -0.21 | -0.57 | -0.85 | -1.94 | -4.38 | 0.31 | 4.12 | 0.54 | 0.22 | -0.02 |
| EPS Diluted | -0.20 | -0.57 | -0.85 | -1.94 | -4.38 | 0.31 | 4.12 | 0.54 | 0.22 | -0.02 |
| Weighted Avg Shares Out | 45.04M | 22.87M | 19.87M | 16.28M | 16.25M | 17.64M | 15.89M | 15.97M | 15.97M | 15.97M |
| Weighted Avg Shares Out (Dil) | 47.17M | 22.87M | 19.87M | 16.28M | 16.25M | 17.64M | 15.89M | 15.97M | 15.97M | 15.97M |
Hexindai to Hold Annual General Meeting on December 16, 2020
Contraceptive Drugs and Devices Market Size Report Forecast 2020 – 2024 Business Revenue, Opportunities, Future Growth, Trends Plans, Top Key Players, Global Analysis by Share
Electrochemical Flow Cells Market Growth, Industry Trends 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact
Financial Contrast: Weidai (NYSE:WEI) vs. Hexindai (NYSE:HX)
Source: https://incomestatements.info
Category: Stock Reports